Advertisement
-
-
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus. In this Review, Ussher and Drucker discuss the possible mechanisms of cardiovascular benefit of GLP1 receptor agonists and highlight the novel GLP1-based multi-agonists currently in development.
-
-

Anticoagulants
Anticoagulant drugs are used to prevent and treat thrombotic disorders in millions of patients worldwide. This Milestone plots the history of anticoagulant drugs, starting with the discovery and clinical trials of heparin and warfarin.
Trending - Altmetric
-
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome
-
Obesity and the risk of cardiometabolic diseases
-
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
-
Omega-3 fatty acids: cardiovascular benefits, sources and sustainability
Events
-
EMBL Conference: Protein synthesis and translational control
-
EMBO | EMBL Symposium: Organoids: modelling organ development and disease in 3D culture
-
American Association for Cancer Research (AACR) Annual Meeting 2023
-
EMBO | EMBL Symposium: The non-coding genome
-
EMBL Course: Plasticity and timing in developing systems
Jobs
-
Research Assistant (f/m/d)
-
Polymer Scientist (m/f/div) for Materials Central Scientific Facility
-
Scientific Computing Associate - Machine Learning Software Engineer
-
BRF Research Officers (Animal Technician)/Support Technicians (Bank Staff)
-
PRODIGY - Postdoctoral Fellowship in Ocean Observation, Analysis and Prediction